A Multicenter Randomized Controlled Study Comparing Endoscopic Ivor-Lewis Versus Laparoscopic Transabdominal Extended Gastrectomy for Siewert II Esophagogastric Junction Adenocarcinoma

What this Trial Is About

Researchers are studying the best surgical method for treating Siewert type II adenocarcinoma of the esophagogastric junction, a condition where tumors occur at the junction between the esophagus and stomach. There is controversy about whether to use a right chest (endoscopic Ivor-Lewis) or left chest (laparoscopic extended abdominal gastrectomy) approach. This trial aims to compare the safety, feasibility, and clinical effectiveness of these two surgical techniques to improve patient outcomes. The study compares two procedures: the endoscopic Ivor-Lewis operation and the laparoscopic transabdominal extended gastrectomy, both used to remove tumors at the esophagogastric junction. Participants are randomly assigned to one of these two surgical methods. The trial is multicenter and randomized, designed to provide new clinical data to help standardize treatment for this specific type of tumor. During the study, participants will be monitored for disease-free survival over three years, with additional follow-up for overall survival up to five years. Researchers will also track postoperative complications, mortality within one month, and tumor recurrence over three years. Assessments include clinical evaluations and imaging before surgery and careful postoperative monitoring to measure treatment outcomes and safety. The total participation duration spans several years to capture these important results.

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction